Details for Patent: 11,400,019

Which drugs does patent 11,400,019 protect, and when does it expire?

Patent 11,400,019 protects POSIMIR and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 11,400,019

Title:	Sustained release drug delivery systems with reduced impurities and related methods
Abstract:	The present disclosure relates to sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises N-oxide of active pharmaceutical agent at a level less than 1 wt %, based on weight of the composition. In some case, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.
Inventor(s):	Miksztal; Andrew R. (Palo Alto, CA), Joice; Judy (San Jose, CA), Autio; Susan (San Jose, CA), Davis; Mark P. (Middleton, WI)
Assignee:	DURECT CORPORATION (Cupertino, CA)
Application Number:	17/504,913
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 11,400,019

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021		RX	Yes	Yes			Y

International Family Members for US Patent 11,400,019

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112022013784
Canada	3167217
China	115666621